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Abstract 
Glioblastoma Multiforme (GBM) is an aggressive brain tumour with high resistance to 
radio- and chemotherapy. As such, increasing attention has focused on developing new 
therapeutic strategies to improve treatment responses. Recently, attention has been 
shifted to natural compounds that are able to halt tumour development. Among them, 
carnosol (CAR), a phenolic diterpene present in rosemary, has become a promising 
molecule that is able to prevent certain types of solid cancer. However, no data are 
available on the effects of CAR in GBM. Here, CAR activity decreased the proliferation of 
different human glioblastoma cell lines, particularly cells that express wild type p53. The 
p53 pathway is involved in the control of apoptosis and is often impaired in GBM. Notably, 
CAR, through the dissociation of p53 from its endogenous inhibitor MDM2, was able to 
increase the intracellular p53 levels in GBM cells. Accordingly, functional reactivation of 
p53 was demonstrated by the stimulation of p53 target genes’ transcription, the induction 
of apoptosis and cell cycle blockade. Most importantly, CAR produced synergistic effects 
with Temozolomide (TMZ) and reduced the restoration of the tumour cells’ proliferation 
after drug removal. Thus, for the first time, these data highlighted the potential use of 
diterpenes in the sensitization of GBM cells to chemotherapy through a direct re-activation 
of p53 pathway. Furthermore, progress has been made in delineating the biochemical 
mechanisms underlying the pro-apoptotic effects of this molecule. 
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1. Introduction 
Phytochemicals are defined as the non-nutritive components in plants and are able to 
influence human health in different ways. Recently, the identification, characterization and 
development of natural chemotherapeutic molecules with anti-cancer properties has 
become a major area of cancer research (Johnson and Mukhtar, 2007; Khuda-Bukhsh, 
2014; Syed, 2007). The anti-cancer activity of a Rosmarinus officinalis extract has been 
widely reported in the literature (Fortes, 2003; Huang 1994; Ngo, 2011; Singletary, 1996). 
Among the different components of rosemary, the diterpene carnosol (CAR) has become 
one of the major bioactive molecules.  
CAR was first isolated in 1942 from Salvia carnosa and possesses a wide range of 
biological activities, namely anti-microbial (Weckesser, 2007), neuroprotective (Kim, 2006), 
anti-oxidant (Pérez-Fons, 2010), anti-inflammatory (Altinier, 2007; Johanson, 2011; 
Poeckel, 2008) and anti-cancer properties (Dörrie, 2001; Huang, 2005; Johanson, 2011; 
Lo, 2002; Vergara, 2014; Visanji, 2006). Regarding its anti-cancer properties, CAR has 
been shown to have significant cytotoxic effects in several human cancer cell lines and 
animal models (Johanson, 2011): HT-1080 human fibrosarcoma cells (López-Jiménez, 
2013), MCF-7 human breast cancer cells (Johnson, 2010), PC3 human prostate cancer 
cells (Johnson, 2008), B-lineage leukaemia cells (Dörrie, 2001) and very recently in human 
colon cancer cells (Park, 2014). The anti-proliferative effects elicited by CAR have been 
demonstrated to be preferentially directed towards cancer cells in both in vivo and in vitro 
models (Johanson, 2011). However, to date, no data have been reported on the effects of 
this diterpene on central nervous system cancers, particularly Glioblastoma multiforme 
(GBM). 
GBM is one of the most aggressive and deadly forms of primary brain tumours in adults. 
GBM treatment usually consists of surgical resection, followed by radiotherapy combined 
with the alkylating agent temozolomide (TMZ) (Sathornsumetee, 2007). Aberrations in 
different intracellular signalling pathways are involved in the pathogenesis of glioma and 
cause the escape from cell death that represents an important hallmark of cancers 
(Mitsutoshi, 2001). In this respect, apoptosis inducers have been emerging as promising 
drugs in a large number of tumours (Green and Walczak, 2013). Among the different 
intracellular pathways, the deregulation of the oncosuppressor protein p53 has been 
widely described, and the reactivation of its endogenous function represents an important 
tool in GBM treatment (England, 2013; Khoo, 2014; Sato, 2011; Villalonga-Planells, 2011). 
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The tumour suppression protein p53 is a transcription factor that regulates cell fate after 
different stresses, and its activation leads to a cell cycle blockade and an increase in 
apoptosis (Kruiswijk, 2015). Accordingly, in vivo studies support the idea of 
pharmacologically restoring p53 functionality in cancer treatment (Xue, 2007; Junttila, 
2010; Feldser, 2010) 
CAR is able to interfere with several intracellular pathways that are deregulated in 
inflammation and cancer (Johanson, 2011). Among the different targets of CAR, Park et al. 
(2014) reported that this natural compound has the ability to increase the intracellular 
expression level of the p53 protein.  
In the present study, for the first time, the anti-proliferative activity of CAR was 
investigated in GBM cells and one of its underlying mechanisms of action was explored in 
depth. CAR was able to decrease the viability of different GBM cell lines; notably, this 
effect was more evident in cells expressing wild-type p53. Therefore, the p53 pathway was 
investigated in depth as one of the possible mechanisms of action of CAR. The results 
demonstrated that CAR had the ability to reactivate p53 pathway, inducing cell cycle arrest 
and apoptosis. Further examinations of the signalling pathways indicated that CAR-
induced cell death was partially linked to the direct dissociation of p53 from its 
physiological inhibitor mouse double minute 2 (MDM2). More interestingly, CAR was able 
to synergize with a traditional anticancer drug (TMZ). Taken together, these findings could 
highlight the mechanisms underlying the anticancer effects of CAR on human GBM cells. 
Furthermore, CAR could represent the starting point for the development of more effective 
chemotherapeutic agents against highly aggressive brain tumours that act as direct 
apoptosis inducers and chemosensitisers in combination with standard chemotherapeutic 
agents.  
2. Experimental 
2.1 Material 
The human glioblastoma U87MG, T98G and U343MG cell lines were obtained from the 
National Institute for Cancer Research of Genoa (Italy), American Type Culture Collection 
(USA) and Cell Lines Service GmbH (Germany), respectively. Each cell line was 
monitored for DNA profiling. Human Mesenchymal stem cells (MSCs) and cultured media 
MSCGM were purchased from Lonza srl (Milan, Italy). All other reagents were obtained 
from standard commercial sources and were of the highest commercially available grade. 
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2.2 Cell lines.  
The U87MG and T98G cells were cultured in RPMI medium and Minimum essential 
medium Eagle, respectively, supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL 
penicillin, 100 mg/mL streptomycin and 1% non-essential amino acids at 37°C in 5% CO2. 
U343MG cells were cultured in Minimum essential medium Eagle with 2 mM L-glutamine 
and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 
10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, 1% non-essential amino acids 
and 1.0 mM sodium pyruvate at 37°C in 5% CO2.  
Human MSCs were cultured in normal growth medium (MSCGM, Lonza), plated (5 x 
103 cells/cm2) in 75-cm2 flasks and incubated at 37 °C in 5% CO2 and 95% air. The 
medium was changed to remove non adherent cells every 3 to 4 days, and the cells were 
used at passages 0 to 3. 
2.2 Cell viability assays of GBM cells and MSC.  
The human GBM cells or MSCs were seeded at a density of 1.5x103 cells/well or 3x103 
cells/well respectively. After 24h, the cells were treated with fresh growth medium 
containing different concentrations of CAR (Sigma Aldrich, Cat. C9617) (100 nM-100 µM). 
Following the treatment period, cell proliferation was determined using the MTS assay 
(CellTiter 96® AQueous One Solution Cell Proliferation Assay kit; Promega) according to 
manufacturer's instruction. The absorbance of formazan at 490 nm was measured in a 
colorimetric assay with an automated plate reader (Victor Wallac 2, Perkin Elmer). For 
wash-out experiments, U87MG cells were treated with CAR (100 nM-60 µM) or 
Temozolomide (100 µM–250 µM) alone or in combination for 72h. At the end of treatments, 
medium-containing drugs was replaced by fresh medium, and cells were allowed to growth 
for additional 72h. At the end, cell proliferation was measured using MTS assay as 
described above. Data were expressed as the percentage of untreated cells proliferation. 
Sigmoid dose-response curve was generated, from which the IC50 values were derived. 
2.3 siRNA mediated inhibition of p53 expression 
U87MG cells were transfected with a siRNA specifically designed for the silencing of the 
human p53 (sc-29435 Santa Cruz Biotecnology). The siRNAs have been transfected with 
siRNA transfection reagent (sc-29528 Santa Cruz Biotecnology) to a final concentration of 
50 nM, following the manufacturer's protocol. In parallel to each silencing experiment, an 
ineffective sequence of RNA has been used as negative control (sc-37007 Santa Cruz 
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Biotechnology). The efficacy of silencing was verified by real time-RT-PCR. Transfected 
cells were used 48h or 72h after siRNA transfection. 
2.4 RNA extraction and Real Time PCR analysis in U87MG cells.  
U87MG cells were treated with DMSO (control) or CAR (10 µM-20 µM) for 8h or 24h. At 
the end of treatments, cells were collected, and total RNA was extracted using Rneasy® 
Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. cDNA 
synthesis was performed with 500 ng of RNA using i-Script cDNA synthesis kit (BioRad, 
Hercules, USA) following manufacturer’s instructions. Real-time RT-PCR reactions 
consisted of 25 µL Fluocycle® II SYBR® (Euroclone, Milan, Italy), 1.5 µL of both 10 µM 
forward and reverse primers, 3 µL cDNA, and 19 µL of H2O. All reactions were performed 
for 40 cycles using the following temperature profiles: 98 °C for 30 seconds (initial 
denaturation); T °C (Table 1) for 30 seconds (annealing); and 72 °C for 3 seconds 
(extension). Primer used were previously described (Da Pozzo, 2014) and listed in Table 
1. β-actin was used as the housekeeping gene. The mRNA levels for each sample were 
normalized against β-actin mRNA levels, and relative expression was calculated by using 
Ct value. PCR specificity was determined by both the melting curve analysis and gel 
electrophoresis. 
Table 1. Near here 
2.5 Western blotting analysis of p53 protein expression.  
The Western blot analysis for the evaluation of p53 protein levels was performed as 
previously described (Daniele, 2014). In brief, U87MG cells were treated with DMSO 
(control) or with different CAR concentrations for 8h or 24h, and then lysed for 60 min at 4 
°C by the addition of 200 μl RIPA buffer. Equal amounts of the cell extracts (50 μg of 
proteins) were diluted in Laemmli solution, resolved by SDS-PAGE (7.5%), transferred to 
PVDF membranes and probed overnight at 4 °C with primary antibody anti-p53 (diluted 
1:200; FL-393; Santa Cruz Biotechnology) or β-actin (diluted 1:1000; MAB1501, Merck 
KGaA, Darmstadt, Germany). The primary antibody was detected using anti-rabbit IgG 
light chains conjugated to peroxidase (diluted 1:10000; 12-348; Millipore). The peroxidase 
was detected using a chemioluminescent substrate (ECL, Perkin Elmer). Densitometric 
analysis of immunoreactive bands was performed using Image J Software. Western blot 
analysis was also performed using lysates from CAR treated and untreated GBM cells in 
the absence or presence of the protein synthesis inhibitor Cycloheximide (CHX, 50 µM). 
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2.6 Dissociation studies of native MDM2/p53 complex.  
In brief, U87MG cell were suspended in lysis buffer (20 mM Tris HCl, 137 mM NaCl, 
10% glycerol, 1% NONIDET40, 2 mM EDTA, pH 8) containing 1% of the Protease inhibitor 
Cocktail (Sigma Aldrich, Milan, Italy). Cell lysates (20 μg in a final volume of 100 μl) were 
pre-incubated with DMSO (control) or different CAR concentration for 10 minutes at room 
temperature, and then transferred for 60 min to wells pre-coated with a mouse full-length 
anti-MDM2 antibody (sc-965, Santa Cruz Biotechnology, 1:50 in 0.05% Poly-L-Ornithine, 
overnight at room temperature). After washes, each well was incubated for 15 min with 1% 
BSA, to block nonspecific sites, and then for 1.5h at room temperature with a rabbit 
primary anti-p53 antibody (sc-6243, Santa Cruz Biotechnology, 1:250 in 5% milk). Then, 
wells were washed and incubated for 1h with an anti-rabbit IgG HRP-conjugate antibody 
(1:3000 in 5% milk), and washed again. The TMB substrate kit (Thermo Fisher Scientific) 
allowed a colorimetric quantification of the MDM2/p53 complex. Blanks were obtained 
processing cell lysates in the absence of the primary anti-p53 antibody. Absorbance’s 
values at 450 nm were measured and background subtracted.  
2.7 MDM2/p53 co-immunoprecipitation.  
The amount of MDM2/p53 complex in cell was determined using co-
immunoprecipitation experiments; U87MG cells were treated with DMSO (control) or CAR 
(1 µM-10 µM) for 8h. One milligram of cell lysates was pre-cleared with protein A-
Sepharose (1h at 4 °C) to precipitate and eliminate IgG. Samples were then centrifuged for 
10 min at 4 °C (14,000×g). The supernatants were incubated with an anti-MDM2 antibody 
(5 μg/sample) overnight at 4 °C under constant rotation and then immunoprecipitated with 
protein A-Sepharose (2h at 4 °C). After washing, the immunocomplexes were 
resuspended in Laemmli solution and boiled for 5 min, resolved by SDS-PAGE (7.5%), 
transferred to PVDF membranes and probed overnight at 4 °C with anti-p53 (diluted 1:200; 
FL-393; Santa Cruz Biotechnology) or anti-MDM2 (diluted 1:200; C-18; Santa Cruz 
Biotechnology) as described above. 
2.8 RNA extraction and Real Time PCR analysis in U87MG cells.  
U87MG cells were treated with DMSO (control) or CAR (10 µM-20 µM) for 8h or 24h. At 
the end of treatments, cells were collected, and total RNA was extracted using Rneasy® 
Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. cDNA 
synthesis was performed with 500 ng of RNA using i-Script cDNA synthesis kit (BioRad, 
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Hercules, USA) following manufacturer’s instructions. Real-time RT-PCR reactions 
consisted of 25 µL Fluocycle® II SYBR® (Euroclone, Milan, Italy), 1.5 µL of both 10 µM 
forward and reverse primers, 3 µL cDNA, and 19 µL of H2O. All reactions were performed 
for 40 cycles using the following temperature profiles: 98 °C for 30 seconds (initial 
denaturation); T °C (Table 1) for 30 seconds (annealing); and 72 °C for 3 seconds 
(extension). Primer used were previously described (Da Pozzo, 2014) and listed in Table 
1. β-actin was used as the housekeeping gene. The mRNA levels for each sample were 
normalized against β-actin mRNA levels, and relative expression was calculated by using 
Ct value. PCR specificity was determined by both the melting curve analysis and gel 
electrophoresis. 
Table 1. Near here 
2.9 Cell cycle analysis.  
U87MG were treated with DMSO or CAR for 48h. The measurement of the percentage 
of cells in the different cell phases was performed using the Muse™ Cell Analyzer (Merck 
KGaA, Darmstadt, Germany), as described previously (Daniele, 2014). 
2.10 Apoptosis analysis.  
U87MG cells were treated with DMSO (control) or CAR for 48h. At the end of the 
treatment periods, the percentages of living, apoptotic and dead cells were acquired and 
analyzed by Muse™ Cell Analyzer, as previously described (Daniele, 2014). The cells 
positively stained with Annexin V and 7-Aminoactinomycin D (7-AAD) were evaluated to 
distinguish the live, early apoptotic and late apoptotic/dead cells. 
2.111 Measurement of cell migration by in vitro scratch assay.  
CAR effects on U87MG cell migration were evaluated with a scratch assay. U87MG 
were seeded in 96 well plates and grown to 90% of confluence. Then, the scratch was 
made through the cell layer using a sterile micropipette tip. After washing with PBS, cells 
were treated with CAR (1 µM–20 µM) in medium with 1% of FBS. The images of the 
wounded area were captured immediately after the scratch (t0) and 16h later (t16) to 
monitor cell migration into the wounded area. Photographs were then taken at 4× 
magnification on an inverted microscope. The migration abilities were quantified by 
measuring both the average gap width and the percentage of gap closed. The data were 
analysed with the Image J software (Version 1.41o). 
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2.12 Isobolar analysis.  
A graphical assessment of CAR-TMZ synergy with regard to growth inhibition was 
performed using isobolographic analysis (Tallarida, 1999). The IC50 of TMZ was plotted on 
the abscissa, and the iso-effective dose of CAR was plotted on the ordinate. The 
theoretical additive effect of the two drugs is represented by the straight line connecting 
the two points. If the experimentally determined data points and their confidence interval 
fall on this line, the drug effects are additive (no interaction). If the points lie below this line, 
there is superadditivity (synergy), and if the points lie above this line, there is subadditivity 
(antagonism). To determine whether the interaction between the two drugs was 
synergistic, additive or antagonistic, the theoretical additive IC50,add was estimated from the 
dose-response curves of each drug administered individually. The interaction index, 
denoted by γ, is an assessment of the degree of synergism or antagonism. The index is 
defined by the isobolar relationship as follows (Tallarida, 2001,1999): γ = a/A + b/B where 
A and B are the doses of drug A (alone) and B (alone) that give the specified effect, and 
(a,b) are the combination doses that produce the same effect. 
2.13 Statistical analysis.  
The nonlinear multipurpose curve-fitting program Graph-Pad Prism (GraphPad Software 
Inc., San Diego, CA) was used for data analysis and graphic presentations. All data are 
presented as the mean ± SEM. Statistical analysis was performed by one-way analysis of 
variance (ANOVA) with Bonferroni’s corrected t-test for post-hoc pair-wise comparisons. P 
< 0.05 was considered statistically significant. 
3. Results 
3.1 CAR affected cell proliferation.  
The CAR molecule has been demonstrated to have cytotoxic properties that inhibit the 
proliferation of several cancer cell lines (Johanson, 2011). Surprisingly, there have been 
no reports on the effect of the rosemary component on brain tumours. Here, the effects of 
CAR on the U87MG human glioblastoma cell line were investigated. 
CAR treatment (100 nM-60 µM) of the U87MG cells for 24, 48 or 72 h caused a 
significant decrease in proliferation in a time-dependent manner (Fig. 1A-C). This effect 
appeared to be dose-dependent at each time point, yielding IC50 values of 28.9±0.9 µM, 
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14.9±1.0 µM and 10.4±0.5 µM after 24 h, 48 h and 72 h of incubation, respectively (Fig. 
1D).  
To assess whether the U87MG cells could resume proliferation after drug removal, the 
cells were treated with different compound concentrations (100 nM-60 µM) for 72 h, and 
then washed out for additional 72 h in drug-free medium. The U87MG cells’ proliferation 
rate was completely restored when low doses of CAR were added (Fig. 1E). However, the 
cells partially recovered their growth after 72 h of wash-out when CAR was used at 
intermediate doses (20-30 µM), although the percentage of proliferating cells remained 
significantly reduced compared to the control cells. Surprisingly, at high concentrations 
(40–60 µM), CAR completely inhibited the ability of U87MG cells to restore their growth. 
These results suggest that CAR was able to inhibit cell proliferation, and this effect 
appeared to be irreversible only at the highest concentrations tested.  
Then, the effects of CAR on other glioblastoma cell lines were investigated. The 
U343MG cells express wild-type p53 and, similar to the U87MG cells, overexpress MDM2 
(Ishii, 1999). CAR (100 nM–60 µM) treatment led to a significant inhibition of U343MG cell 
viability after both 48 h and 72 h (IC50 = 19.0±1.0 µM and 11.7±1.2 µM, respectively, Fig. 
2A; Fig. S1). The results are comparable with those observed in the  U87MG cells (Fig. 
1B-C) and are in accord with the reported data on the anti-proliferative effects of CAR in 
other cell lines that express wild-type p53 (Park, 2014; Tai, 2012).  
Conversely, the rosemary metabolite on T98G cells (Wang, 2006), which expressed a 
mutated p53 isoform, was able to produce a significant right shift of the anti-proliferative 
dose-response curve respect to those obtained in the other GBM cell lines at both 48 and 
72 h (Fig. 2B). The data support the hypothesis that the reactivation of the p53 pathway 
may be involved in the CAR-mediated effects. 
To confirm this, a viability assay was performed in p53-silenced, CAR-treated U87MG 
cells (Fig. 2C-E). The efficiency of the siRNA transfection in reducing P53 gene expression 
was demonstrated by real time RT-PCR (Fig. 2C). The anti-proliferative activity of CAR 
was then evaluated. After 48 h of treatment, CAR alone decreased the U87MG cells’ 
proliferation at different rates in the negative control (CTRL -) and the p53-silenced cells 
(IC50 = 14.8±4.3 µM, Fig. 2D; Fig. S2). These differences were maintained after 72 h of 
treatment (IC50 = 12.8±2.7 µM, Fig. 2E; Fig. S2). However, p53 knock down was not 
sufficient to completely inhibit the anti-proliferative action of CAR, thus demonstrating that 
p53 reactivation is only one of several death mechanisms activated by CAR. 
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Finally, the CAR selectivity towards healthy cells was investigated. Considering the tight 
relationship between glioblastoma cells and the mesenchymal stem cell homing (Ho, 2013; 
Nakamizo, 2006), the selectivity of CAR was evaluated by measuring human 
Mesenchymal Stem Cells’ (MSCs’) viability. The MSCs were treated with CAR (100 nM-
100 μM) for 48 h (Fig. 3A-B) or 72 h (Fig. 3C-D), and cell proliferation was measured using 
the MTS assay. CAR was able to induce a slight but significant reduction in MSC 
proliferation at the highest concentration (60 μM). However, the percentages of viable 
MSCs were significantly higher than those observed in the U87MG cells after both 48 h 
(MSC: 74.6±2.1% versus U87MG 17.3±2.7%) and 72 h (MSC: 56.5±1.1% versus U87MG 
9.8±1.8%) of treatment. These data highlight the presence of a favourable therapeutic 
window for the use of the diterpene derivative as a chemotherapeutic agent. 
 
3.2 Effects of CAR on p53 reactivation 
3.2.1 Intracellular p53 levels 
The effect of CAR on the p53 pathway was investigated in depth in the U87MG cell line. 
CAR treatment of U87MG cells for 8 and 24 h caused an increase in the intracellular levels 
of the p53 protein, as demonstrated by western blot analysis (Fig. 4A) and densitometric 
quantification of the immunoreactive bands (Fig. 4B). This effect was dose-dependent and 
was already significant at 10 μM CAR after 8 h of cell treatment (121.0±4.3 percent 
increase in the p53 levels versus the control, which is in accord with previously reported 
data (Park, 2014)). 
It is well known that different mechanisms could increase the intracellular p53 levels, 
such as de novo protein synthesis or the dissociation of the MDM2/p53 complex (Costa, 
2013; Daniele, 2014; Khoo, 2014; Kruiswijk, 2015). Therefore, a potential increase in the 
p53 mRNA levels was first analysed by real-time RT-PCR (Fig. 4C). Surprisingly, CAR 
(10–20 µM) treatment for 8 h did not significantly change the levels of the p53 transcript 
(Fig. 4C). Because it has been shown that the increases in mRNA levels may not be 
directly correlated to protein expression (Maier 2009), the intracellular levels of the p53 
protein were measured in the presence of the protein synthesis inhibitor, CHX. The 
U87MG cells were treated with CAR alone or with CAR and CHX for 8 h (Fig. 4D-E). CHX 
alone, which affects the synthesis of new proteins, was able to significantly decrease the 
p53 levels with respect to the control. CAR alone increased the intracellular p53 levels. 
Notably, CHX only slightly decreased the CAR-mediated up-regulation of p53 (CHX: 
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52.9±10.6%; 10 µM CAR + CHX: 142.3±13.5% versus the control). The results suggested 
that CAR did not affect p53 translation.  
Therefore, the ability of the rosemary metabolite to modulate the stability of the 
MDM2/p53 complex was investigated using a direct quantitative sandwich immuno-
enzymatic ELISA assay (Daniele, 2014). The MDMD2/p53 complex that was presented in 
the U87MG crude lysates was incubated with different concentrations of CAR (1 nM–50 
µM). Then, the amount of remaining complex was measured (Fig. 4F). CAR directly 
dissociated the MDM2/p53 complex, with a maximum percent of dissociation of 45.1±4.8% 
(versus control set to 100%) at 1 µM CAR. Accordingly, the data were comparable to the 
dissociation induced by Nutlin-3 (38.4±6.3%), which was used as a control (Daniele, 
2014). 
A co-immunoprecipitation assay was performed to confirm the ability of CAR to 
dissociate the MDM2/p53 complex in whole cells. A significant decrease in p53 was 
detected in the MDM2 immunoprecipitates after 8 h of treatment with CAR at the IC50 
concentration (Fig. 4G-H).  
As expected, the CAR concentrations that were able to induce significant dissociation of 
the complex differed in the isolated complex (1 µM; Fig. 4F) and the whole cells (10 µM; 
Fig. 4G-H). This is likely due to the ability of CAR to permeate the cell, as well as its 
interaction with other proteins in the whole cells. 
 
3.2.2 p53 gene transcription 
Functional reactivation of p53 has been widely correlated to increases in specific p53-
related genes (Costa, 2013; Daniele, 2014; Khoo, 2014; Kruiswijk, 2015). Thus, a real-time 
RT-PCR analysis of the p53-related genes was performed after the U87MG cells were 
treated with CAR (10–20 µM) for 8 or 24 h. CAR was able to significantly increase the 
mRNA levels of all of the p53 target genes (Fig. 5A-B): p21 (with a maximum increase of ≈ 
2.4-fold), PUMA (with a maximum increase of ≈ 1.6-fold), and MDM2 (with a maximum 
increase of ≈ 3.4-fold).  
Then, the expression of other genes that are correlated to p53 reactivation was 
investigated. The expression of the pro-apoptotic 'multi-domain' Bcl-2 family member Bax 
and the anti-apoptotic protein Bcl-2 was assessed by real-time RT-PCR analysis. As 
expected, CAR treatment of the U87MG cells caused a significant increase in Bax 
(maximum increase of ≈ 1.6-fold) and a concomitant decrease in Bcl-2 (maximum 
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decrease of ≈ 0.6-fold) (Fig. 5A-B). The results are in accordance with previously reported 
data showing that CAR modulates Bcl-2 family proteins in other cell lines (Chun, 2014; 
Dörrie, 2001; Park, 2014). 
3.3 Apoptosis and cell cycle block 
Challenging U87MG cells with CAR for 48 h induced significant phosphatidylserine 
externalization, both in the absence (early apoptosis) and presence of 7-Aminoactinomycin 
D (7-AAD) binding to DNA (late apoptosis/death). Apoptosis was significantly induced in 
cells that were treated with 20 µM CAR (Fig. 5C-D), the same concentration that was able 
to stimulate the expression of the PUMA mRNA (Fig. 5B).  
Functional reactivation of p53 in proliferating cells is tightly correlated to the activation of 
the cyclin-dependent kinase inhibitor p21 and the subsequent cell cycle arrest at both G1 
and G2 phases (Concin, 2003; Taylor, 2001). Therefore, a cell cycle cytofluorimetric assay 
was performed (Fig. 4E). CAR dose-dependently affected the cell cycle, causing a 
decrease in the DNA content in G1/G0 phase and a concomitant increase in the number of 
cells in G2/M and S phases. These data suggest that CAR caused a cell cycle block in G2 
phase (Fig. 4E) in accordance with data previously reported in other cell lines (prostate 
cancer PC3 cells (Johnson, 2008) and MDAMB-231 cells (Al Dhaheri, 2014)), and it was 
associated with an up-regulation of the CDK inhibitor p21. 
The increase in the transcriptional activity of p53, along with the induction of apoptosis 
and the block of cell cycle demonstrate the ability of CAR to restore the function of p53 
and highlight its role in the balance of pro-apoptotic/anti-apoptotic signals in favour of 
apoptosis induction and proliferation arrest. 
3.4 U87MG cell migration  
GBM is a highly aggressive tumour due to its invasiveness and chemoresistance 
(Stupp, 2005). Metastasis is the main cause of mortality in cancer, while the key process 
of metastasis is the migration and invasion of cancer cells into adjacent tissues 
(Hoelzinger, 2005). 
A wound healing assay was performed to assess the effects of CAR on the migration of 
U87MG cells. CAR treatment for 16 h significantly inhibited the cells’ migration compared 
to the untreated control cells, as observed by optical microscopy (Fig. 6A). These effects 
were dose-dependent, and cell motility was abrogated at the highest concentration (20 
µM). This effect could be partially due to the ability of CAR to block the cell cycle and 
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reduce the U87MG cells’ viability. However, CAR caused a significant inhibition in cell 
migration also at the 1 µM concentration, which did not affect cell viability (Fig. 6B-C).  
These results highlighted that CAR was not only able to affect GBM cell proliferation but 
was also able to control the tumour cells’ migration that is the basis for cancer 
invasiveness. 
 
3.5 CAR synergizes with TMZ to induce U87MG cell death. 
Another main feature of GBM is its poor response to therapy and rapid development of 
drug-resistance. In this respect, a multi-target or combined therapy has been considered a 
valid tool to overcome this problem (Zimmermann, 2007). To this end, the effect of a 
combination of CAR and TMZ was investigated by an isobolographic analysis. 
TMZ inhibited cell viability in a dose-dependent manner, with an IC50 value in the 
micromolar range (169.1±14.8 µM) (Fig. 7A), which is in accord with previously reported 
data (Torres, 2011). Based on the calculated IC50 values for CAR and TMZ alone, the 
theoretical additive IC50,add values for CAR/TMZ were calculated for two fixed ratios (1:3 
and 1:25) (Table 2). Then, the dose-response curves of U87MG viability were measured 
for the same fixed-ratio combinations and the experimental IC50,mix values was calculated 
(Table 2, Figure 7B). A statistical analysis of the data from the isobolographic analysis 
revealed slight synergistic interactions between CAR and TMZ for the three examined 
fixed-ratio combinations (Table 2, Fig. 7B). Indeed, the interaction index values of the 
combinations are ≤ 1. However, the synergistic effect was more evident when a ratio of 
1:25 (CAR/TMZ) was used.  
To assess whether U87MG cells resumed proliferation after TMZ and CAR treatment, 
the cells were washed out in drug-free medium for additional 72 h (Fig. 7C). The U87MG 
cells’ proliferation rate was completely restored when TMZ or CAR (at low concentration) 
were used alone. Conversely, the combined treatment caused a decrease in cell 
proliferation compared to the single treatment. Notably, the combination of TMZ and the 
highest CAR concentration (20 µM) was able to completely inhibit the ability of the U87MG 
cells to restore their growth (Fig. 7C). 
These results suggest that CAR may have chemosensitizing properties and may be 
able to synergize with classical chemotherapeutic agents to reduce the cells’ ability to 
resume proliferation after chemotherapy. 
Insert Table 2 near here 
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4. Discussion 
In this study, we found that the diterpene CAR exerted an anti-proliferative effect in the 
U87MG cell line through a mechanism that involves the functional reactivation of p53. In 
addition, CAR synergized with TMZ to induce irreversible cell death, at least at high 
concentrations.  
The discovery of different phytochemicals has become a tool in anticancer therapy 
(Khuda-Bukhsh, 2014). Secondary metabolites obtained from different plants extracts 
have been widely used in the treatment of cancer (Cragg, 2005; Newman, 2007). 
However, GBM remains a challenging disease to treat, primarily due to its extreme 
complexity and heterogeneity (Kleihues, 2002). Indeed, several intracellular pathways are 
de-regulated, highlighting the need for molecules that are able to interfere with different 
intracellular targets. Here, CAR was demonstrated to inhibit the proliferation of GBM cell 
lines that present different genetic features.  
CAR inhibited the glioblastoma cells’ proliferation and this effect was more evident in 
U87MG cells expressing wild-type p53, in accord with previously reported data (Park, 
2014; Tai, 2012). A lower activity was observed in p53-mutated T98G cells, a typical cell 
model that is used as a negative control for studies analysing the reactivation of p53 
function (Villalonga-Planells R, 2011), and in p53-silenced cells. In parallel, previous 
reports demonstrate that CAR is also effective in cells that lack wild-type p53 (p53-null 
PC3 cells (Al Dhaheri, 2014) and p53-mutant MDA-MB-231 and R280K cells (Johnson, 
2008)), but with a lower activity than that observed in cells expressing the wild-type p53 
protein. These data highlighted the involvement of the p53 pathway in the anti-proliferative 
activity of CAR. However, the contributions of other additional mechanisms cannot be 
excluded. 
U87MG is a GBM cell line that is characterized by a defective p53 pathway. Although 
these cells express wild-type p53, the functional activity of this oncosuppressor protein is 
impaired as a consequence of the over-expression of the physiological p53 inhibitor 
mouse double minute 2 (MDM2) (Costa, 2013; Halatsch, 2006; Kondo, 1995; Kim, 2011).  
Notably, CAR was able to increase the intracellular level of p53. These results were not 
due to de novo synthesis of the protein; furthermore, the inability of CHX, a protein 
synthesis inhibitor, to counteract the effect of CAR on p53 indicates that the primary effect 
of CAR was likely to inhibit p53 degradation. In fact, one of the mechanisms underlying 
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p53 stabilization is the direct dissociation of the MDM2/p53 complex (Costa, 2013; 
Daniele, 2014). Several molecules with different chemical structures have been reported to 
interfere with the MDM2/p53 interaction, mainly due to several conformational adjustments 
(Uhrinova, 2005, Arkin, 2003) in the p53 and MDM2 interaction 
Here, for the first time, CAR was demonstrated to stabilize p53 by directly dissociating 
the MDM2/p53 complex. The discrepancy between its ability to directly dissociate the 
complex and its anti-proliferative effect is an issue that has been already reported in the 
literature for other MDM2/p53 inhibitors. In particular, Nutlin-3 dissociates MDM2/p53 
complex in a “cell-free” model with an IC50 value in the nanomolar range. However, the 
anti-proliferative effect on glioblastoma and other cancers is only exerted at higher 
concentrations that are at least 10-fold higher than the IC50 values for the complex 
dissociation (Costa, 2013b; Daniele, 2014; Künkele, 2012). In accordance, CAR was able 
to interfere with the formation of the MDM2/p53 complex, presenting the same profile of 
Nutlin-3. 
p53 activation induced the expression of multiple genes involved in the control of cell 
death/survival (Khoo, 2014; Kruiswijk, 2015; Costa, 2013; Daniele, 2014), such as p21 
(also known as p21WAF1/Cip1), which promotes cell cycle arrest; the p53 upregulated 
modulator of apoptosis (PUMA), a critical mediator of p53-dependent apoptosis; and 
MDM2, which forms a negative feedback loop with p53 (Wagner, 2005). We demonstrated 
that CAR induced a significant up-regulation of these p53 gene targets. The induction of 
MDM2 and PUMA mRNA expression by CAR has been demonstrated for the first time. 
Conversely, the results for p21 expression are in accord with the increase in this transcript 
shown in other cell lines (Al Dhaheri, 2014; Chun, 2014). 
It has been demonstrated that p53 activation is also correlated with the expression of 
different Bcl-2 family genes (Hemann and Lowe, 2006), including pro-apoptotic (e.g., Bax, 
p53, and PUMA) and anti-apoptotic genes (e.g., Bcl-2), in different cells. It is well known 
that the alteration of the balance between the pro-apoptotic and anti-apoptotic genes is the 
basis for the modulation of cell death (Fabregat, 2007; Kruiswijk, 2015). CAR was able to 
modulate the expression of these p53-related genes to regulate cellular apoptosis. These 
data are in agreement with previous reports demonstrating that the anticancer effect of 
CAR on leukaemia (Dörrie, 2001), prostate cancer (Johnson, 2008; Lopez-Jimenez, 2013), 
breast cancer (Al Dhaheri, 2014) and colon cancer (Park, 2014) cell lines was due to the 
activation of the apoptotic pathway of cell death. Thus, the anti-proliferative effects of CAR 
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were exerted by the increase in p53 function and the subsequent blockade of cell cycle 
progression and the induction of apoptosis. 
Accumulating in vitro and in vivo data have shown that natural chemopreventive agents 
enhance the efficacy of chemotherapy and radiotherapy in various cancers by regulating 
different intracellular pathways (Khuda-Bukhsh, 2014). CAR is able to induce apoptosis in 
chemoresistant ovarian cancer cells (Tai, 2012) and radiosensitises melanoma cells after 
radiotherapy (Alcaraz, 2013). The ability of CAR to sensitize other cancer lines was also 
demonstrated in glioblastoma cells for the first time.  
TMZ is an alkylating agent that is used as a first-line chemotherapeutic agent in 
glioblastoma. CAR was able to synergize with the anti-proliferative effect of TMZ. In the 
conventional protocol for the treatment of brain tumours (for example with TMZ), the 
chemotherapeutic agent is administered after the surgical removal in different cycles, with 
a latency of several days (Ryu, 2014). In this period, even if the drug is cleared, the effect 
of the drug on the cancer cells could be important. Therefore, the cells’ ability to resume 
proliferation was measured after the drug was removed from the culture medium to mimic 
the other chemotherapeutic agents. Surprisingly, higher doses of CAR were able to 
irreversibly inhibit the U87MG cells’ viability after the drugs were removed. One hypothesis 
that could explain these results is the sustained activation of the p53 pathway. In this 
experimental condition, the threshold of irreversible TMZ damage could be lower and 
trigger an irreversible death mechanism. However, additional investigations should be 
performed to assess this hypothesis and better clarify this issue.  
The selectivity of anti-tumour agents on cancer cells versus non-malignant cells is an 
important issue that must be considered to avoid several side effects. The anti-proliferative 
effects elicited by CAR were preferentially directed towards cancer cells, as reported in 
both animal and in vitro models (Johanson, 2011). In particular, Johanson et al. (2011) 
demonstrated that CAR did not affect the viability of prostate epithelial cells. CAR 
presented a favourable therapeutic window, indicating that the rosemary derivative could 
be used as a possible chemotherapeutic agent. No hypotheses have been reported in the 
literature that explain the selectivity of CAR for tumour cells. However, it was able to 
interfere with the intracellular pathways that are deregulated in tumour cells (e.g., p53), 
and the selective modulation of these pathways may be crucial for the selective balance 
between the survival and death of tumour cells. Nevertheless, few data have been 
reported regarding the differences in p53 expression or mechanism of cell membrane 
permeation and intracellular stability of CAR, between the two cell models, thus 
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highlightening the need of further experiment to better clarify the different activity of CAR in 
cancer cells versus non-malignant cells. 
Taken together, these data demonstrate the ability of CAR to affect different features of 
GBM, such as proliferation, invasiveness and resistance to therapy, in combination with 
selectivity towards the tumour cell.  
In conclusion, the discovery of the ability of CAR to modulate the glioblastoma cells’ 
proliferation by reactivating p53 functionality could represent the starting point for the 
development of more effective drugs that act as apoptosis inducers. Moreover, the 
synergistic effect of CAR with a standard chemotherapeutic drug highlights the possible 
use of the rosemary extract in the diet as a co-adjuvant in chemotherapy. 
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Figure Legends 
 
Fig. 1. Effects of CAR on U87MG cell viability. The cells were treated with the indicated 
concentrations of CAR in complete medium for 24 h (A), 48 h (B) or 72 h (C). D) Non-
linear regression of the CAR dose-response curve after 24 h, 48 h or 72 h. E) The U87MG 
cells were treated with CAR (100 nM-60 µM) for 72 h, and the cells were subsequently 
washed out in drug-free medium for an additional 72 h. At the end of the treatments, cell 
proliferation was measured using the MTS assay, as described in the Methods section. 
The data were expressed as a percentage with respect to the untreated cells (control), 
which was set to 100%, and they were presented as the mean values ± SEM of three 
independent experiments, each performed in triplicate. The significance of the differences 
was determined by one-way ANOVA, followed by Bonferroni’s post hoc test: *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001 vs. the control; # P ≤ 0.05, ### P ≤ 0.001 vs. the cells treated for 72 h. 
 
Fig. 2. Effects of CAR on the proliferation of different GBM cell lines. The U343MG (A) and 
T98G (B) cells were treated with different concentrations of CAR for 48 h or 72 h. At the 
end of the treatments, cell proliferation was measured using the MTS assay. C) The 
efficiency of p53 silencing was assessed by evaluating the expression of the p53 mRNA 
using real time RT-PCR. The data were normalized to the β-actin levels, expressed as fold 
changes compared to the control (without siRNA), which was set to 1, and are presented 
as the means ± SEM of at least three different experiments. ***P<0.001 vs the control. The 
negative control and p53-silenced U87MG cells were treated with the indicated 
concentrations of CAR in complete medium for 48 h (D) or 72 h (E). At the end of the 
treatments, cell proliferation was measured using the MTS assay, as described in the 
Methods section. The data were expressed as a percentage with respect to the untreated 
cells (control), which was set to 100%, and were presented as the mean values ± SEM of 
three independent experiments, each performed in triplicate. The significance of the 
differences was determined by one-way ANOVA, followed by Bonferroni’s post hoc test: 
**P ≤ 0.01, ***P ≤ 0.001 vs. the control. 
 
Fig. 3. Effect of CAR on MSC proliferation. The MSCs were treated with the indicated 
concentrations of CAR in complete medium for 48 h (A) or 72 h (C). Non-linear regression 
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of the CAR dose-response curve after 48 h (B) or 72 h (D). At the end of the treatments, 
cell proliferation was measured using the MTS assay, as described in the Methods 
section. The data were expressed as a percentage with respect to the untreated cells 
(control), which was set to 100%, and they were the mean values ± SEM of three 
independent experiments, each performed in triplicate. The significance of the differences 
was determined by one-way ANOVA, followed by Bonferroni’s post hoc test: **P ≤ 0.01, 
***P ≤ 0.001 vs. the control. 
 
Fig. 4. p53 stabilization and CAR-induced MDMD2/p53 dissociation. A, B) The U87MG 
cells were treated with DMSO (control) or CAR for 8 h or 24 h and the levels of the p53 
protein were evaluated by western blotting. C) The cells were treated with CAR (10 µM–20 
µM) for 8 h and a Real Time RT-PCR analysis of the p53 mRNA expression levels was 
performed. The data were expressed as the fold change compared to the levels of the 
control, which was set to 1, and were the mean values ± SEM of three different 
experiments. D, E) The cells were treated with DMSO (control) or CAR in the absence or 
presence of CHX (50 µM) for 8 h. At the end of the incubation, the cells were lysed and a 
western blot analysis using a p53 antibody was performed. The data are expressed as the 
percentage of the optical density of the immunoreactive bands compared to the control, 
which was set to 100%, and are presented as the mean values ± SEM of three different 
experiments. F) U87MG cell lysates containing the native MDM2/p53 complex were pre-
incubated with DMSO (control) or different concentrations of CAR. Then, the lysates were 
captured on wells that had been pre-coated with an MDM2 antibody. The levels of the 
MDM2/p53 complex were quantified using a specific p53 antibody. The data are 
expressed as the % of MDM2/p53 complex versus the control, which was set to 100%, 
and represent the means ± SEM of three independent experiments performed in duplicate. 
G, H) The U87MG cells were incubated with CAR for 8 h, followed by immunoprecipitation 
using an anti-MDM2 antibody. The MDM2/p53 complex and the relative input proteins 
were detected by p53 immunoblotting. One representative western blot is presented (G). 
The bar graph (H) shows the quantitative analysis of the western blot, which was 
performed using the ImageJ programme. The data are presented as the means ± SEM of 
three different experiments. The significance of the differences was determined by one-
way ANOVA, followed Bonferroni’s post hoc test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. 
the control; ## P ≤ 0.01 vs. the CHX alone group. 
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Fig. 5. Functional reactivation of p53 and the effects of CAR on gene transcription, the cell 
cycle and apoptosis. The U87MG cells were treated with CAR (10 µM–20 µM) for 8 h (A) 
or 24 h (B). At the end of the incubation, a Real Time RT-PCR analysis of the p53 target 
genes (p21, MDM2, PUMA, Bax and Bcl-2) was performed. The data were expressed as 
the fold change versus the levels of the control, which were set to 1, and were the mean 
values ± SEM of three different experiments. C, D) The U87MG cells were treated with 
DMSO (control) or CAR (1 µM-60 µM) for 48 h. At the end of the treatments, the cells were 
collected and the amount of phosphatidylserine externalization was evaluated using the 
Annexin V staining protocol. The distribution of the live, early and late apoptotic cells were 
shown (C), as well as the total number of apoptotic cells (D). The data were expressed as 
the percentage of apoptotic cells versus the total cell number and were presented as the 
means ± SEM of three different experiments. E) The U87MG cells were treated with 
DMSO (control) or CAR (1 µM-40 µM) for 48 h and the cell cycle was analysed. The 
subpopulations of cells in the different cellular phases were shown. The data were 
expressed as the percentage of cells in the different phases (G0/G1, G2/M or S) versus 
the total cell number, and they were the mean values ± SEM of three different 
experiments. The significance of the differences was determined by one-way ANOVA, 
followed by Bonferroni’s post hoc test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. the control. 
 
Fig. 6. Effect of CAR on U87MG cell migration. The cells were treated with CAR (1 µM–20 
µM), and the healing of the scratch wounds was evaluated. A) Representative images of 
the scratch wounds at 0 h and 16 h. B) The average widths of the gaps of five scratch 
wounds was initially measured at 0 h (t0) and then measured after 16 h (t16). The data are 
presented as the means ± SEM of at least two different experiments performed in 
triplicate. **P<0.01, ***P<0.001 vs. the respective average gaps at t0. C) The percentage 
of gap closure compared to the untreated cells (control). The data are presented as the 
means ± SEM of at least two different experiments performed in triplicate. The significance 
of the differences was determined by one-way ANOVA, followed by Bonferroni’s post hoc 
test: ## P ≤ 0.01, ### P ≤ 0.001 vs. the control.  
 
Fig. 7. The synergistic effect of CAR and TMZ. A) Non-linear regression of the TMZ dose-
response curve after 72 h of treatment. At the end of the treatments, cell proliferation was 
measured using the MTS assay. The data were expressed as a percentage with respect to 
the untreated cells (control), which was set to 100%, and they were the mean values ± 
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SEM of three independent experiments, each performed in triplicate. B) The isobologram 
shows the interactions between CAR and TMZ in the MTS viability tests performed in the 
U87MG cells that had been treated for 72 h. The IC50 values for TMZ and CAR are shown 
on the X- and Y-axes, respectively. The open points on the additivity line depict the 
theoretical IC50,add values. The solid points depict the experimental IC50,mix values for total 
dose, which is expressed as the proportion of CAR and TMZ that produced a 50% effect. 
C) The U87MG cells were treated with CAR alone or in combination with the indicated 
concentration of TMZ for 72 h, and the cells were subsequently washed out for additional 
72 h in drug-free medium. At the end of the treatments, cell proliferation was measured 
using the MTS assay, as described in the Methods section. The data were expressed as a 
percentage with respect to the untreated cells (control), which was set to 100%, and they 
were the mean values ± SEM of three independent experiments, each performed in 
triplicate. The significance of the differences was determined by one-way ANOVA, 
followed by Bonferroni’s post hoc test: *P ≤ 0.05, ***P ≤ 0.001 vs. the control; °P ≤ 0.05, 
°°P ≤ 0.01, °°°P ≤ 0.001 vs. the respective cells treated for 72 h; # P ≤ 0.05, ## P ≤ 0.01, 
### P ≤ 0.001 vs. the respective TMZ treatment; § P ≤ 0.05, §§§ P ≤ 0.001 vs. the 
respective CAR treatment. 
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 Gene Primer nucleotide sequences 
Product size  
(base pairs) 
MDM2 
FOR: 5’-TCTAGGAGATTTGTTTGGCGT-3’ 
REV: 5’-TCACAGATGTACCTGAGTCC-3’ 125 bp 
p21 
FOR: 5’-TGCCGAAGTCAGTTCCTTG -3’ 
REV: 5’-CATGGGTTCTGACGGACATC-3’ 134 bp 
BAX 
FOR: 5’-TTTGCTTCAGGGTTTCATCC-3’ 
REV: 5’-CAGTTGAAGTTGCCGTCAGA-3’ 245 bp 
PUMA 
FOR: 5′-GAGGAGGAACAGTGGGC-3′ 
REV: 5′- CTAATTGGGCTCCATCTCGG-3′ 198 bp 
p53 
FOR: 5′-CTTTGAGGTGCGTGTTTGTG-3′ 
REV: 5′-GTGGTTTCTTCTTTGGCTGG-3′ 161 bp 
Bcl-2 
FOR: 5′-GAGGATTGTGGCCTTCTTTG-3′ 
REV: 5′-ACAGTTCCACAAAGGCATCC-3′ 171 bp 
NF-kB 
FOR: 5′-GCTCCGGAGACCCCTTCCA-3′ 
REV: 5′-GGTTTGAGGTAGTTTCCCAGT-3′ 198 bp 
β-actin FOR: 5’-GCACTCTTCCAGCCTTCCTTCC-3’ REV: 5’-GAGCCGCCGATCCACACG-3’ 254 bp 
Table 1. Primers Used for Real-Time RT-PCR. 
 
 
  
CAR/TMZ  
ratio 
IC50,mix (µM) IC50,add (µM) 
calculated 
γ 
CAR 10.4 ± 0.5 - - 
TMZ 160.4 ± 12.4 - - 
1:3 21.0 ± 3.5* 36.2 0.9 
1:25 50.6 ± 5.4*** 105.1 0.7 
 
Table 2. Isobolographic analysis of CAR and TMZ in U87MG. Data are presented as IC50 
± S.E.M. Statistical analysis was performed with Student’s t-test. *P ≤ 0.05, ***P ≤ 0.001 vs 
the respective additive group. γ<1 indicates supra-additivity (synergy). 
 
